Please login to the form below

Not currently logged in

OPEN Health names Rob Barker chief executive officer

Barker succeeds outgoing OPEN Health CEO and co-founder David Rowley

OPEN Health Group has appointed Rob Barker (pictured above) as its new chief executive officer (CEO), succeeding outgoing CEO and co-founder David Rowley.

OPEN Health, a portfolio company of Amulet Capital Partners, is a multidisciplinary health communications and market access group.

Barker has approximately 30 years of executive leadership experience in the biopharmaceutical industry, having held a number of roles at medical communications and strategy consulting firms.

Most recently, he served as the CEO of OPEN Health’s Medical Communications practice, which he joined six years ago.

“I am excited to be leading such a talented and expert team which has been instrumental in growing OPEN Health to its current position,” commented Barker.

“We are now in a place to take even greater strides forward, and I feel confident that our continued focus on client service and scientific excellence will drive increased growth in the business,” he added.

Outgoing CEO David Rowley said: "I have been CEO of OPEN Health since its inception, and I am incredibly proud of the company that we have built. This is the right time for me to be stepping down, and I wish Rob and the whole OPEN Health team continued success."

Article by
Lucy Parsons

19th November 2020

From: Marketing


PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...